Eden Rahim, portfolio manager and options strategist at Next Edge Capital, discusses the news that the U.S. federal health agencies are recommending an immediate “pause” in the use of Johnson & Johnson’s single-dose COVID-19 vaccine after six U.S. recipients developed a rare disorder involving blood clots. He said in the grand scheme, these events are rare but the headlines might cause some Canadians to become hesitant about getting the vaccine.